Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases

ABSTRACT

A method for enhancing the therapeutic effect of a stem cell on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell. A method of stem cell treatment is also provided, comprising administering to a subject suffering from autoimmune diseases, cardiovascular diseases, and/or hematological diseases an effective amount of a stem cell or a combination of ligustilide and a stem cell, wherein the stem cell has been treated with ligustilide.

This application is a Division of U.S. application Ser. No. 14/552,014,filed Nov. 24, 2014, which claims priority to Taiwan Patent ApplicationNo. 103132044 filed on Sep. 17, 2014, in the Taiwan IntellectualProperty Office, the disclosure of which is incorporated herein in itsentirety by reference.

BACKGROUND OF THE INVENTION

1. Field

The present invention relates to the use of ligustilide, especially tothe use of ligustilide in stem cell treatment, in particular the use ofligustilide in stem cell treatment of a stroke. The therapeutic effectof the stem cells can be enhanced by treating the stem cells withligustilide. In particular, the treatment of ligustilide can increasethe expression of differentiation-promoting genes in the stem cells,increase the expression of homing-promoting genes in the stem cells,and/or decrease the expression of inflammatory genes in the stem cells.In addition, the present invention also relates to a combined use ofligustilide and ligustilide-treated stem cells, which provides a moreefficient therapeutic effect of stem cell treatment.

2. Descriptions of the Related Art

Stem cells, depending on their abilities to self-renew and todifferentiate, can be classified into the following four types:totipotent stem cells, pluripotent stem cells, multipotent stem cellsand unipotent stem cells. Depending on the appearance order during thedevelopmental process and distributional profile of stem cells, stemcells can be classified into the following two types: embryonic stemcells (ES cells) and adult stem cells. In addition, researchers haveshown that cell differentiation is reversible. By introducing specificgenes into fully differentiated matured somatic cells, the maturedsomatic cells are induced to reprogram and form pluripotent cells withcharacteristics and functions similar to those of an embryonic stemcell, i.e., to form induced pluripotent stem cells (iPS cells). Theseinduced pluripotent stem cells can differentiate into tissues of thehuman body, and thus, can be used in the research and therapy of thedisease.

Currently, in the field of medical research, stem cell therapy bringshope to the patients suffering from diseases which lack effectivetreatment, such as diabetes mellitus, autoimmune rejection, stroke,myocardial infarction, renal failure, leukemia, muscular dystrophy,severe anemia, Alzheimer's disease, Parkinson's disease, and cancer. Thepluripotency of stem cells may solve the long-term predicament that isencountered in the treatment of these diseases.

For example, strokes are the most common neurological system disease.Depending on the cause, strokes can be classified as either ischemic orhemorrhagic. According to statistical data, a stroke is one of the topten leading causes of death in the world. However, only fewanti-coagulant drugs or thrombolytic agents can be used for treatingstrokes, and these drugs and agents are not suitable for every patientssuffering from stroke. Therefore, there is an urgent necessity for anovel therapeutic method. Stem cell therapy is by far the most potentialtherapeutic method in clinical trials. In 1998, stem cell therapy wasfirst applied to the treatment of strokes. Over recent years, the U.S.Food and Drug Administration (FDA) has approved the clinical use of stemcells to treat stroke patients.

Researchers have shown that stem cells indeed have a therapeutic effecton treating stroke, however, the survival rate of stem cells after beingtransplanted into a subject's body was unfavorable. Therefore, there isa necessity and urgency for developing a method or a drug for enhancingthe therapeutic effect of stem cells effectively to improve the diseasecure rate.

Inventors of the present invention found that stem cells treated withligustilide can provide an enhanced therapeutic effect. In addition, thetherapeutic effect provided by a combination of ligustilide andligustilide-treated stem cells is better than that provided by usingligustilide-treated stem cells independently.

SUMMARY OF THE INVENTION

An objective of the present invention is to provide a method forenhancing the therapeutic effect of a stem cell, comprising treating thestem cell with ligustilide, wherein the treatment is conducted in aculture medium of the stem cell.

Another objective of the present invention is to provide a compositionfor enhancing the therapeutic effect of a stem cell, comprisingligustilide.

Yet another objective of the present invention is to provide a stem cellkit with an enhanced therapeutic effect, comprising a stem cell, aculture medium for the stem cell, and ligustilide. Preferably, theligustilide comprises a first part and a second part, wherein the firstpart is used in combination with the culture medium to pre-treat thestem cell, and the second part is used in combination withligustilide-treated stem cells in a stem cell therapy.

Yet another objective of the present invention is to provide a use ofligustilide in the manufacture of a medicament, wherein the medicamentis used in combination with ligustilide-treated stem cells in a stemcell therapy.

Yet another objective of the present invention is to provide a method ofstem cell treatment, comprising administering to a subject in need aneffective amount of stem cells, wherein the stem cells have been treatedwith ligustilide. Preferably, the method comprising administering to thesubject in need ligustilide and stem cells separately or simultaneously,wherein the stem cells have been treated with ligustilide.

The detailed technology and preferred embodiments implemented for thepresent invention are described in the following paragraphs accompanyingthe appended drawings for people skilled in this field to wellappreciate the features of the claimed invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B are statistical bar diagrams showing the percentages ofthe survival rate of adipose-derived stem cells (ADSCs) which have beentreated with ligustilide for 24 or 48 hours, wherein the vertical axisrepresents the survival rate of the cells and the horizontal axisrepresents the concentration of ligustilide;

FIG. 2 is a photograph showing the expression of different genes in stemcells which have been treated with different concentration ofligustilide and analyzed by RT-PCR, wherein such genes includedifferentiation-promoting genes (i.e., BDNF and NURR1), homing-promotinggenes (i.e., CXCR4 and SDF1αβ) and inflammatory genes (i.e., IL-6 andIL-8);

FIG. 3 is a curve diagram showing the coordination of mice which havebeen treated with different conditions and analyzed by Rotarod Analysis,wherein the horizontal axis represents the time post-treatment and thevertical axis represents the running time of the mice; wherein Group 1is a non-stroke mouse without treatment (i.e., a pseudo-operationgroup), Group 2 is a stroke mouse administered with saline, Group 3 is astroke mouse administered with stem cells without being treated withligustilide, and Group 4 is a stroke mouse administered withligustilide-treated stem cells;

FIGS. 4A and 4B are curve diagrams showing the balance ability of micewhich have been treated with different conditions and analyzed by BeamWalking Analysis. FIG. 4A represents the time required for the mice topass through the balance beam at different days post-treatment; and FIG.4B represents the foot-fault score of the mice at different dayspost-treatment, wherein Group 1 is a non-stroke mouse without treatment(i.e., a pseudo-operation group), Group 2 is a stroke mouse administeredwith saline, Group 3 is a stroke mouse administered with stem cellswithout being treated with ligustilide, and Group 4 is a stroke mouseadministered with ligustilide-treated stem cells;

FIGS. 5A and 5B are curve diagrams showing the balance ability of micewhich have been treated in different conditions and analyzed by BeamWalking Analysis. FIG. 5A represents the time required for the mice topass through the balance beam at different days post-treatment, and FIG.5B represents the foot-fault score of the mice at different dayspost-treatment, wherein Group 1 is a non-stroke mouse without treatment(i.e., a pseudo-operation group), Group 2 is a stroke mouse administeredwith saline, Group 3 is a stroke mouse administered with stem cellswithout being treated with ligustilide, Group 4 is a stroke mouseadministered with ligustilide-treated stem cells, Group 5 is a strokemouse administered with ligustilide-treated stem cells and 30 mg/kg-bodyweight of ligustilide simultaneously; and Group 6 is a stroke mouseadministered with ligustilide-treated stem cells and 90 mg/kg-bodyweight of ligustilide simultaneously; and

FIGS. 6A and 6B are curve diagrams showing the motor ability of micewhich have been treated with different conditions and analyzed byLocomotor Activity Box Test. FIG. 6A represents the total traveleddistance of the mice at different days post-treatment; and FIG. 6Brepresents the movement time of the mice at different dayspost-treatment, wherein Group 1 is a non-stroke mouse without treatment(i.e., a pseudo-operation group), Group 2 is a stroke mouse administeredwith saline, Group 3 is a stroke mouse administered with stem cellswithout being treated with ligustilide, Group 4 is a stroke mouseadministered with ligustilide-treated stem cells, Group 5 is a strokemouse administered with ligustilide-treated stem cells and 30 mg/kg-bodyweight of ligustilide simultaneously; and Group 6 is a stroke mouseadministered with ligustilide-treated stem cells and 90 mg/kg-bodyweight of ligustilide simultaneously.

DESCRIPTION OF THE PREFERRED EMBODIMENT

The following will describe some embodiments of the present invention indetail. However, without departing from the spirit of the presentinvention, the present invention may be embodied in various embodimentsand should not be limited to the embodiments described in thespecification. In addition, unless otherwise indicated herein, theexpressions “a,” “the,” or the like recited in the specification of thepresent invention (especially in the claims) are intended to include thesingular and plural forms. Furthermore, the term “effective amount” or“amount effective for treatment” used in this specification refers tothe amount of the compound that can at least partially alleviate thecondition that is being treated in a suspected subject when administeredto the subject in need. The term “subject” used in this specificationrefers to a mammalian, including human and non-human animals.

As well-known in the art, stem cells can be used in the application oftreating autoimmune diseases (e.g., diabetes mellitus and autoimmunerejection), treating digestive diseases (e.g., anus/digestive fistuladiseases), treating hepatic diseases (e.g., hepatocirrhosis and hepaticfibrosis), treating renal diseases (e.g., renal failure), treatingcardiovascular diseases (e.g., stroke and myocardial infarction),treating neurological diseases (e.g., Alzheimer's disease andParkinson's disease), treating hematological diseases (e.g., leukemia),treating bone degeneration (e.g., degenerative arthritis, degenerationof knee cartilage), treating periodontitis, treating tendonitis,treating spinal injury, treating head trauma, plastic surgery (e.g.,hemifacial atrophy and sunken scar), treating alopecia, whitening skin,and/or eliminating wrinkles. The aforementioned description can be seenin, for example, “Stem cells: innovations in clinical applications. StemCells int. Volume 2014, Article ID 516278, 9 pages,” which is entirelyincorporated hereinto by reference.

However, the survival rate of stem cells was unfavorable after beingtransplanted into a subject's body. Researchers have proven that theprimary cause of this phenomena is that stem cells may induce aninflammatory reaction after being transplanted into a subject's body. Ifthe expressions of inflammatory factors in stem cells can be decreased,the inflammatory reaction induced by stems cells after beingtransplanted into a subject's body can be reduced. Therefore, thesurvival rate of stem cells will be increased and the therapeutic effectof stem cells will be enhanced. The aforementioned description can beseen in, for example, “Qptimizing the success of cell transplantationtherapy for stroke. Neurobiol Dis. 37:275-283 (2010),” which is entirelyincorporated hereinto by reference.

It has also been proven that if the expressions ofdifferentiation-promoting genes in stem cells can be increased, thedifferentiation of the stem cells into tissue of the body can bepromoted, and thus, is favorable for the application of stem cells intreating diseases. On the other hand, if the expression ofhoming-promoting genes in stem cells can be increased, the stem cellswill be promoted to locate into the impaired target tissue and performits repair function to achieve the effect of treating diseases even ifthe stem cells are administered as an intravenous injection to thesubject. The aforementioned description can be seen in, for example,“Journey of mesenchymal stem cells for homing: strategies to enhanceefficacy and safety of stem cell therapy. Stem Cell Int. Volume 2012,Article ID 342968, 11 pages;” and “Concise review: Mesenchymal stem celltumor-homing: detection methods in disease model systems. Stem Cells.29(6):920-927 (2011),” which are entirely incorporated hereinto byreference.

Inventors of the present invention found that treating stem cells withligustilide can effectively increase the expression ofdifferentiation-promoting genes therein, increase the expression ofhoming-promoting genes therein, and decrease the expression ofinflammatory genes therein, wherein the differentiation-promoting genesinclude Nuclear receptor-related factor 1 (NURRJ) and brain-derivedneurotrophic factor (BDNF); the homing-promoting genes include C—X—Cchemokine receptor type-4 (CXCR4) and stromal cell-derived factor-1αβ(SDF1αβ); and the inflammatory genes include interleukin-6 (IL-6) andinterleukin-8 (IL-8).

Researchers have further confirmed that treating stem cells withligustilide can effectively improve the therapeutic effect of the stemcells. Therefore, the present invention relates to a discovery aboutenhancing the therapeutic effect of stem cells that provides acomposition and a method for enhancing the therapeutic effect of stemcells. The composition comprises ligustilide, and the method comprisestreating a stem cell with ligustilide in a culture medium of the stemcell. The phrase “treating the stem cell with ligustilide in a culturemedium of the stem cell” used in this specification means that whenconducting the treatment, the stem cells were placed in a culture mediumof the stem cells.

The composition and method of the present invention can be used in anysuitable stem cells and include, for example, an embryonic stem cell, anadult stem cell, and an induced pluripotent stem cell. The adult stemcells include, for example, a hematopoietic stem cell, a mesenchymalstem cell, an umbilical cord blood stem cell, a peripheral blood stemcell, a neural stem cells, an epithelial stem cell, a muscle stem cell,an adipose-derived stem cell, a pancreas stem cell, a limbal stem cell,a hepatic stem cell, and an intestinal stem cell. In one embodiment, thecomposition and method of the present invention are used to enhance thetherapeutic effect of the adipose-derived stem cells (ADSCs), forexample, the effect of treating strokes.

According to the present invention, if stem cells are pre-treated with acomposition comprising ligustilide before being used in stem celltherapy, the therapeutic effect thereof will be enhanced. Theligustilide-comprising composition can be ligustilide itself, or caninclude ligustilide and a solvent, wherein ligustilide is dissolved intothe solvent. For example, ligustilide may be added into the culturemedium which corresponds to the stem cell that is to be treated toprovide the composition of the present invention, the composition isthen used for treating stem cells. In another example, ligustilide maybe added into a solvent, such as DMSO or ethanol, to provide acomposition of the present invention, the composition is then used fortreating stem cells. Alternatively, when the composition is ligustilideitself, the composition can be directly added into the culture mediumwhich contains the stem cell that is to be treated to perform apre-treatment. With a provision, to maintain the activity of the stemcells, the pre-treating method of the present invention shall beconducted in a culture medium of the stem cells. Therefore, if thecomposition for treating the stem cells of the present invention doesnot comprise a culture medium of the stem cells, the stem cells that areto be treated should be placed in a culture medium of the stem cells toconduct the pre-treatment.

Any suitable culturing conditions can be chosen and used depending onthe type of stem cell. In general, the amount of ligustilide may rangefrom about 0.1 μg to about 40 μg, preferably from about 0.1 μg to about20 μg, and most preferably from about 0.1 μg to about 10 μg permilliliter of the culture medium for stem cells. For instance, asillustrated in the examples provided hereinafter, when ligustilide isused in the pre-treatment of ADSCs, the amount of ligustilide preferablyranges from about 0.5 μg to about 5 μg per milliliter of the culturemedium for stem cells, this amount can effectively increase theexpression of differentiation-promoting genes in the ADSCs, increase theexpression of homing-promoting genes in the ADSCs, and decrease theexpression of inflammatory genes in the ADSCs.

Any suitable culture medium of stem cells can be used in the presentinvention, as long as the culture medium corresponds to the stem cellsthat are to be treated. The components of the culture medium of stemcells may be adjusted depending on the types of the stem cells that areto be treated. In general, a culture medium of stem cells comprises abase culture medium, an animal serum (e.g., fetal bovine serum),non-essential amino acids (NEAA) and L-glutamine, etc. Examples of thebase medium suitable for the method of the present invention include,but are not limited to, K-SFM (keratinocyte-Serum Free Medium), DMEM(Dulbecco's Modified Eagle's Medium), MEM (Minimum Essential Medium),α-MEM (α-Minimum Essential Medium), BME (Basal Media Eagle), MEM/F12medium, Ham's F10 medium, Ham's F12 medium, and RPMI (Rosewell ParkMemorial Institute). For instance, when the method of the presentinvention is used for enhancing the therapeutic effect of ADSCs, K-SFMmay be used as the base medium to conduct pre-treatment.

Accordingly, the present invention also provides a stem cell kit with anenhanced therapeutic effect of the stem cell, comprising (1) a stemcell; (2) a culture medium for the stem cell; and (3) ligustilide. Theselection of the stem cells and culture medium, as well as the conditionand method of using ligustilide are all in line with the abovedescriptions.

Usually, the components (1), (2) and (3) of the kit of the presentinvention are packaged and stored separately, and could be transported,sold separately or in a set. Component (1), (2) and (3) is combined witheach other at the customer's facility prior to being used according tothe preset culture procedure and processes.

The inventors of the present invention also found that when ligustilideis used in combination with ligustilide-treated stem cells in a stemcell therapy, a preferable therapeutic effect can be provided.Therefore, the kit of the present invention may comprise a first part ofligustilide and a second part of ligustilide, wherein the first part isused in combination with the culture medium to pre-treat the stem cells,and the second part is used in combination with the ligustilide-treatedstem cells in a stem cell therapy.

Therefore, the present invention also relates to a use of ligustilide inthe manufacture of a medicament, wherein the medicament is used incombination with a ligustilide-treated stem cell. The selection of stemcells, as well as the condition and method of using ligustilide are allin line with the above descriptions.

The medicament provided by the present invention can be used incombination with ligustilide-treated stem cells for at least one of thefollowing: treating autoimmune diseases (e.g., diabetes mellitus andautoimmune rejection), treating digestive diseases (e.g., anus/digestivefistula diseases), treating hepatic diseases (e.g., hepatocirrhosis andhepatic fibrosis), treating renal diseases (e.g., renal failure),treating cardiovascular diseases (e.g., stroke and myocardialinfarction), treating neurological diseases (e.g., Alzheimer's diseaseand Parkinson's disease), treating hematological diseases (e.g.,leukemia), treating bone degeneration (e.g., degenerative arthritis,degeneration of knee cartilage), treating periodontitis, treatingtendonitis, treating spinal injury, treating head trauma, plasticsurgery (e.g., hemifacial atrophy and sunken scar), treating alopecia,whitening skin and eliminating wrinkles. In one embodiment of thepresent invention, the medicament is used in combination withligustilide-treated stem cells for treating strokes.

The medicament provided by the present invention can be manufacturedinto any form, and can be administered in any suitable form. Forexample, the medicament can be administered by oral, subcutaneous, nasalor intravenous to a subject in need, but is not limited thereby.Depending on the form and purpose, the medicament can further comprise apharmaceutically acceptable carrier.

For oral administration, the medicament manufactured by the presentinvention can comprise a pharmaceutically acceptable carrier that wouldnot adversely affect the desired activity of ligustilide. Examples ofthe carrier include solvents (e.g., water, saline, dextrose, glycerol,ethanol or its analogs, or a combination thereof), oily solvents,diluents, stabilizers, absorption retarders, disintegrants, emulsifiers,antioxidants, adhesives, lubricants, moisture absorbents, solid carriers(e.g., starch and bentonite). The medicament can be provided in anysuitable form for oral administration, such as a tablet, a capsule, agranule, a powder, a fluid extract, a solution, syrup, a suspension, anemulsion, a tincture, etc.

For subcutaneous or intravenous administration, the medicamentmanufactured by using ligustilide of the present invention can compriseone or more component(s), such as an isotonic solution, a saline buffersolution (e.g., a phosphate buffer solution or a citrate buffersolution), a solubilizer, an emulsifier, 5% sugar solution, and othercarriers, etc., to provide the medicament as an intravenous injection,an emulsion intravenous injection, a powder injection, a suspensioninjection, or a powder-suspension injection. Alternatively, themedicament can be prepared as a pre-injection solid. The pre-injectionsolid can be provided as a form which may dissolve into, suspend inother solutions, or be emulsified. In addition, prior to theadministration into a subject in need, the pre-injection solid can bedissolved into, suspended in other solutions, or be emulsified, toprovide a desired injection form.

Optionally, the medicament manufactured by using ligustilide of thepresent invention may comprise other flavoring agents, toner, orcoloring agents to enhance the taste and visual appeal of the resultantmedicament. A suitable amount of a preservative, a conservative, anantiseptic, an anti-fungus reagent, and etc., may also be added toimprove the storability of the resultant medicament. In addition, themedicament may further comprise one or more active components or be usedin combination with a medicament comprising one or more other activecomponents to further enhance the effects of the medicament or toincrease the application flexibility and adaptability of the formulationthus provided, as long as the other active components have no adverseeffect on the desired effect of ligustilide.

Depending on the requirements of the subject, the medicamentmanufactured by using ligustilide of the present invention, can beapplied with various administration frequencies, such as once a day,several times a day or once every few days, etc. For example, when themedicament manufactured by using ligustilide of the present invention isused in combination with the ligustilide-treated stem cells for treatinga stroke in a human body, the dosage of the medicament is about 1 mg (asligustilide)/kg-body weight to about 120 mg (as ligustilide)/kg-bodyweight per day, preferably about 10 mg (as ligustilide)/kg-body weightto about 95 mg (as ligustilide)/kg-body weight per day, and morepreferably about 20 mg (as ligustilide)/kg-body weight to about 40 mg(as ligustilide)/kg-body weight per day, wherein the unit “mg/kg-bodyweight” means the dosage required per kg-body weight of the treatedsubject. However, for patients with acute conditions, the dosage can beincreased to several times or several tens of times, depending on thepractical requirements. In one embodiment of the present invention,ligustilide is used in the use of manufacturing medicament, wherein themedicament is used in combination with the ligustilide-treated stemcells and the dosage of the medicament is about 30 mg (asligustilide)/kg-body weight or about 90 mg (as ligustilide)/kg-bodyweight.

The present invention also relates a method of stem cell treatment,comprising administering ligustilide-treated stem cells to a subject inneed. In addition, the method may optionally comprise administeringadditional ligustilide and ligustilide-treated stem cells, eithersimultaneously or separately, to a subject in need. The treatment ofstem cells, selection of materials, dosage of ligustilide foradministration, and the application of relative therapy are all in linewith the above descriptions.

The present invention will be further illustrated in detail withspecific examples as follows. However, the following examples areprovided only for illustrating the present invention, and the scope ofthe present invention is not limited thereby.

EXAMPLES A. Cellular Experiments Example 1 Examination of Cell SurvivalRate (MTT Assay)

Adipose stem cells (ADSCs) were cultured in keratinocyte-serum freemedium (K-SFM; Gibco) at 37° C. in 5% CO₂. The K-SFM was added withbovine pituitary extract (Gibco), recombinant epidermal growth factor(Gibco), N-acetyl-L cysteine (with a final concentration of 2×10⁻³ M;Sigma), L-ascorbicacid 2-phosphate sesquimagnesium salt hydrate with a(final concentration of 2×10⁻⁴ M; Sigma), and 10% of fetal bovine serum(FBS; Hyclone).

The above ADSCs-containing culture medium was divided into A and Bgroups. Each group has 8 sub-groups. Different concentrations (0, 0.625,1.25, 2.5, 5, 10, 20 and 40 μg/ml) of (Z)-ligustilide were added intoeach sub-groups to conduct a treatment for 24 hours in group A, and 48hours in group B. Then,3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)analytic reagent was used to stain the cells, and the absorbance at awavelength of 570/630 nm (OD₅₇₀₋₆₃₀) of the samples were measured by avisible spectrometer and the data were calculated to understand whetherligustilide will affect the survival rate of ADSCs. The results of groupA and B are shown in FIGS. 1A and 1B.

Example 2 The Effects of Ligustilide on Increasing the Expression ofDifferentiation-Promoting Genes, Increasing the Expression ofHoming-Promoting Genes, and Decreasing the Expression of InflammatoryGenes

Experiment (1) Treat Stem Cells with Ligustilide

ADSCs were cultured in the K-SFM as prepared in Example 1 at 37° C. in5% CO₂. The ADSCs were divided into 5 groups, and each group was treatedwith different concentrations (0, 0.625, 1.25, 2.5, 5 and 10 μg/ml) of(Z)-ligustilide for 24 hours, respectively.

Experiment (2) Preparation of Total RNA of the Stem Cells

The culture medium were removed from each group of stem cells inExperiment (1), then 1 ml of TRIzol reagent (Invitrogen) was added intoeach well and incubated at room temperature for 5 minutes. The stemcells were scraped by using a spatula and placed into a 1.5 mlmicrotube. Then, the cells were lysed completely, and 0.2 ml oftrichloromethane (CHCl₃) was added into the microtube. The microtube wasshaken up and down for 15 seconds and incubated at room temperature for2 to 3 minutes. The mixture was centrifuged (at 12000 g for 15 minutesat 4° C.). The supernatant was transferred into another 1.5 mlmicrotube, and 0.5 ml of isopropanol was added therein and mixedcompletely. The mixture was incubated at room temperature for 10 minutesand then centrifuged (at 12000 g for 10 minutes at 4° C.). Thesupernatant was removed. The remained sediment was washed with 1 ml of75% ethanol-containing DEPC water (i.e. diethylpyrocarbonate-treatedH₂O) and centrifuged (7500 g at 4° C. for 5 minutes) again. Thesupernatant was removed. The remained sediment was dried byvacuum-pumping. The dried sediment was dissolved in about 0.01 ml to0.02 ml of DEPC water to obtain total RNA of ADSCs of experimental groupand blank group, respectively. The absorbance at a wavelength of 260 nm(OD₂₆₀) of the samples were determined by a spectrophotometer (DU-800,Beckman) to evaluate the concentration of RNA. Then, the RNA was storedat −80° C. and used in the following Experiment (3).

Experiment (3) Reverse Transcription Polymerase Chain Reaction (RT-PCR)and Gel Electrophoresis

The effects of ligustilide on increasing the expression ofdifferentiation-promoting genes (e.g., BDNF and NURR1), increasing theexpression of homing-promoting genes (e.g., CXCR4 and SDF1αβ), anddecreasing the expression of inflammatory genes (e.g., IL-6 and IL-8)was analyzed by reverse transcription polymerase chain reaction(RT-PCR), wherein the gene expression of glyceraldehyde 3-phosphatedehydrogenase (GAPDH) was served as a control group, and the steps weredescribed as follows.

The total RNA provided in the above Experiment (2) was reversetranscribed into cDNA. 2.5 μl of each primer (10 pM) shown in Table 1A,7.5 μl of ddH₂O, and 12.5 μl of EconoTaq® PLUS GREEN 2X Master Mix(Lucigen, Middleton, Wis., USA) were mixed with 2.5 μl of the cDNA. Themixture was placed in a RT-PCR machine. The reaction conditions were setas follows: i) 94° C. for 30 seconds, 55° C. for 30 seconds, and 94° C.for 60 seconds, with 30 cycles of the aforesaid steps; ii) 72° C. for 10minutes; and iii) cooling to 4° C. to stop the reaction

The obtained RT-PCR product was analyzed by 1.5% agarose gelelectrophoresis for 30 minutes (voltage: 100 volts (V)). Then, the gelwas placed in and stained with ethidium bromide (EtBr) for 10 minutes,and photographed by a gel image documentation system (DOC PRINTDP-001FDC, VilberLourmat France). The results are shown in FIG. 2. Theexpression levels of the genes were quantified by a software, Image J.The results are shown in Table 1B.

TABLE 1A Name Nucleotide sequence of primer SEQ ID NO. BDNF Forward:   15′-GAGCTGAGCGTGTGTGACAG-3′ Reverse:   2 5′-ACTGGGTAGTTCGGCACTGG-3′ NURR1Forward:   3 5′-CGCACATGATCGAGCAGAGG-3′ Reverse:   45′-ATTCCGGCGACGCTTGTCCA-3′ CXCR4 Forward:   5 5′-GGCCTTCATCAGTCTGGACC-3′Reverse:   6 5′-AGTAAGGCAGCCAACAGGCG-3′ SDF1αβ Forward:   75′-ATGAACGCCAAGGTCGTGGTC-3′ Reverse:   85′-CTTGTTTAAAGCTTTCTCCAGGTACT-3′ IL-6 Forward:   95′-TGCCAGCCTGCTGACGAAGC-3′ Reverse:  10 5′-TCTGTGCCCAGTGGACAGGT-3′ IL-8Forward:  11 5′-GCTGGCCGTGGCTCTCTTGG-3′ Reverse:  125′-TCCACAACCCTCTGCACCCA-3′ GAPDH Forward:  135′-GGAGCCAAACGGGTCATCATCTC-3′ Reverse:  14 5′-GAGGGGCCATCCACAGTCTTCT-3′

TABLE 1B 0 μg/ml 0.625 μg/ml 1.25 μg/ml 2.5 μg/ml 5 μg/ml BDNF 4851.775411.77 4915.77 7069.72 5083.65 NURR1 0.00 0.00 0.00 6694.43 3360.55CXCR4 4136.94 2744.11 3719.23 6539.03 4138.77 SDF1αβ 2482.23 6766.314065.23 4791.36 5767.31 IL-6 13621.92 7756.00 8204.13 5629.93 2804.03IL-8 9302.18 6102.10 9691.71 5840.23 3487.33 GAPDH 7179.84 6892.267615.03 8186.79 8265.67

As shown in FIG. 2 and Table 1B, as compared to the control group (i.e.,GAPDH), the gene expression levels of NURR1, BDNF, CXCR4 and SDF1αβ wereincreased because of the treatment of ligustilide, while the geneexpression levels of IL-6 and IL-8 were decreased because of thetreatment of ligustilide. The results indicate that ligustilide caneffectively increase the expression of differentiation-promoting genes,increase the expression of homing-promoting genes, and decrease theexpression of inflammatory genes, thereby decreasing inflammatoryreaction in stem cells and increasing the survival rate of stem cells.

B. Animal Experiments Example 3 Establishment of the Stroke Mouse Model

To avoid the influence of oppression and anxiety that is caused by notadapting to the caging environment on the procedures and results of theexperiments, male BALB/c mice were given several days to adapt to theenvironment after being separated into individual cages, and analyzed bya neurobehavioral study one day before being induced to form thrombus intheir middle cerebral artery (MCA) by thrombin.

Before the surgery, each male BALB/c mouse (8-week-old and weight 25 g)was anesthetized with 0.25 ml of 4% chloral hydrate. During the surgery,isoflurane was used consistently to keep the mice anesthetized toprevent the mice from becoming conscious during the surgery andaffecting the experimental results.

After anesthetization, a mouse were positioned in a stereotaxic headframe. The skin 1 mm posterior to the right orbit of the mouse wasbiopsied to expose the connective tissue and muscle. The biopsied skinand muscle were lifted and fixed bilaterally. Then, a miniature electricdrill was used to conduct open-skull surgery on the mouse. First, acircular area of skull was biopsied from the top of the malar bone ofthe mouse. Then, a microscope was used to find the middle cerebralartery, and a Laser Doppler Flowmetry probe was set at 1 mm from the topof the middle cerebral artery to detect the blood flow of mouse beforethrombin injection and after thrombin injection. The glass probe set ona microinjector was used to suck up 1 μl of thrombin, and then themicroinjector was placed on a hydraulic 3-way regulating instrument andmoved to gradually approach the middle cerebral artery. After the glassprobe passes through the meninges and inserts into the blood vessel,thrombin was immediately injected into the middle cerebral artery by apneumatic pump. After 10 minutes, the glass probe was gradually removedand a stroke mouse model was obtained, hereinafter referred to as“stroke group” (injected with thrombin). Additionally, a group that wasnot treated with thrombin injection was used as a “pseudo-operationgroup.”

Example 4 Treating the Stroke Mouse with Stem Cell Therapy

ADSCs were cultured in K-SFM at 37° C. in 5% CO₂ and pre-treated with2.5 μg/ml of ligustilide for 24 hours to obtain “ligustilide-treatedstem cells”. In addition, ADSCs without ligustilide pre-treatment wasreferred to as “untreated stem cells.” Before being injected into themouse brain, both the aforesaid stem cells were stained with Hoechst dyefor 1 hour for follow-up tracking.

Within 2 hours post-surgery, the aforesaid “ligustilide-treated stemcells” were injected into three sites of the brain of the “stroke group”mouse provided in Example 3 (each mouse was injected with a total amountof 1×10⁶ cells of the “ligustilide-treated stem cells”), thus a“stroke+ligustilide-treated stem cells group” was obtained, wherein theinjection sites can be seen in, for example, “Enhancement ofneuroplasticity through upregulation of beta1-integrin in humanumbilical cord-derived stromal cell implanted stroke model. NeurobiolDis. 27(3):339-353 (2007),” which is entirely incorporated hereinto byreference. In addition, a “stroke+untreated stem cells group” would beobtained from the “stroke group” mouse injected with the “untreated stemcells,” while the control group was “stroke group” mouse injected withequal value of saline, hereinafter referred to as “stroke+saline group.”

Example 5 Ligustilide Enhances the Therapeutic Effect of Stem Cells

The “Pseudo-operation group (i.e., Group 1)” mouse provided in Example3, “stroke+saline group (i.e., Group 2)” mouse provided in Example 4,“stroke+untreated stem cells group (i.e., Group 3)” mouse provided inExample 4, and “stroke+ligustilide-treated stem cells group (i.e., Group4)” mouse provided in Example 4 were analyzed by a neurobehavioral testsone day before conducting the therapy and 1, 3, 7, 14 days post-therapy,respectively. The neurobehavioral tests includes Rotarod Analysis andBeam Walking Analysis.

In Rotarod Analysis, the running time of the mouse on the roller wasused to evaluate the coordination of mouse. The results are shown inFIG. 3. A longer running time of the mouse represents a bettercoordination. In Beam Walking Analysis, the mouse was placed on abalance beam. The time required for mouse to pass through the balancebeam and number of foot-faults (i.e., foot-fault score) were recorded toreflect the balance ability of the mouse. The results are shown in FIGS.4A and 4B.

As shown in FIG. 3, the running time of “stroke+ligustilide-treated stemcells group” mouse on the roller was significantly more than that of the“stroke+untreated stem cells group” mouse. This result indicates thatthe “stroke+ligustilide-treated stem cells group” mouse has bettercoordination than that of the “stroke+untreated stem cells group” mouse.

As shown in FIG. 4A, the “stroke+ligustilide-treated stem cells group”mouse requires less time to pass balance beam than that of the“stroke+untreated stem cells group” mouse. The time required for themouse 3 days post-therapy of ligustilide-treated stem cells to pass thebalance beam was shortened significantly. In addition, as shown in FIG.4B, the foot-fault score of the “stroke+ligustilide-treated stem cellsgroup” mouse was significantly lower than that of the “stroke+untreatedstem cells group” mouse. The aforesaid results indicate that the mousetreated with ligustilide-treated stem cells has a better balance abilityand the balance ability was recovered significantly in 3 dayspost-therapy.

The above results indicate that ligustilide actually has an effect ofenhancing the therapeutic effect of stem cells.

Example 6 Use a Combination of Ligustilide and Ligustilide-Treated StemCells to Treat Diseases

In addition to “pseudo-operation group (i.e., Group 1),” “stroke+salinegroup (i.e., Group 2),” “stroke+untreated stem cells group (i.e., Group3),” and “stroke+ligustilide-treated stem cells group (i.e., Group 4),”(Z)-ligustilide (30 mg/kg-body weight or 90 mg/kg-body weight) and“ligustilide-treated stem cells” provided in Example 4 were used incombination to inject into the brain of a stroke mouse, which referredto as “stroke+ligustilide-treated stem cells+ligustilide (30 mg/kg-bodyweight) group (i.e., Group 5)” and “stroke+ligustilide-treated stemcells+ligustilide (90 mg/kg-body weight) group (i.e., Group 6),”respectively. The aforesaid six groups were analyzed by Beam WalkingAnalysis and Locomotor Activity Box Test one day before conducting thetherapy and 1, 3, 7, 14 days post-therapy, respectively. The results ofBeam Walking Analysis are shown in FIGS. 5A and 5B, and the results ofLocomotor Activity Box Test are shown in FIGS. 6A and 6B. LocomotorActivity Box Test was conducted through a computer-connecting sensor todisplay and record the movement data of mouse in the Locomotor activitybox. The movement data, that includes horizontal displacement (e.g.,walking), vertical displacement (e.g., head-up and climbing) and totaldistance traveled, were recorded and analyzed statistically to show themotor ability of the mouse.

As shown in FIGS. 5A and 5B, as compared to the“stroke+ligustilide-treated stem cells group” mouse, the time requiredfor “stroke+ligustilide-treated stem cells+ligustilide (30 mg/kg-bodyweight) group” mouse and “stroke+ligustilide-treated stemcells+ligustilide (90 mg/kg-body weight) group” mouse to pass thebalance beam were shorter significantly, and the foot-fault score werealso reduced significantly, wherein the “stroke+ligustilide-treated stemcells+ligustilide (30 mg/kg-body weight) group” mouse has the mostobvious efficiency thereof. The aforesaid results indicate that thestroke mouse treated with “ligustilide” and “ligustilide-treated stemcells” in combination has a better balance ability. In particular, thebalance ability of the stroke mouse treated with “30 mg/kg-body weightof ligustilide” and “ligustilide-treated stem cells” in combination wasrecovered most significantly.

As shown in FIGS. 6A and 6B, the total distance traveled and movementtime of the “stroke+ligustilide-treated stem cells+ligustilide (30mg/kg-body weight) group” mouse and the “stroke+ligustilide-treated stemcells+ligustilide (90 mg/kg-body weight) group” mouse in the Locomotoractivity box were all significantly longer than that of the“stroke+ligustilide-treated stem cells group” mouse, wherein the“stroke+ligustilide-treated stem cells+ligustilide (30 mg/kg-bodyweight) group” mouse has the most obvious efficiency thereof. Theaforesaid results indicate that the stroke mouse treated with“ligustilide” and “ligustilide-treated stem cells” in combination has abetter motor ability. In particular, the motor ability of the strokemouse treated with “30 mg/kg-body weight of ligustilide” and“ligustilide-treated stem cells” in combination was recovered mostsignificantly.

The above results indicate that a combination of “ligustilide” and“ligustilide-treated stem cells” can actually further enhance thetherapeutic effect of stem cells.

The above examples are used to illustrate the principle and efficacy ofthe present invention but not used to limit to the present invention.People skilled in this field may proceed with a variety of modificationsand replacements based on the disclosures and suggestions of theinvention as described without departing from the technical principleand spirit thereof. Therefore, the scope of protection of the presentinvention is that as defined in the claims as appended.

1-12. (canceled)
 13. A method for enhancing the therapeutic effect of astem cell on autoimmune diseases, cardiovascular diseases, and/orhematological diseases through increasing the expression ofdifferentiation-promoting genes in the stem cells, increasing theexpression of homing-promoting genes in the stem cells, and/ordecreasing the expression of inflammatory genes in the stem cells,comprising treating the stem cell with ligustilide, wherein thetreatment is conducted in a culture medium of the stem cell.
 14. Themethod as claimed in claim 13, wherein the stem cell is an embryonicstem cell, an adult stem cell, or an induced pluripotent stem cell. 15.The method as claimed in claim 13, wherein the stem cell is anadipose-derived stem cell.
 16. The method as claimed in claim 13,wherein the amount of ligustilide ranges from 0.1 μg to 40 μg permilliliter of the culture medium.
 17. The method as claimed in claim 13,which is for enhancing the efficacy of the stem cell on treating stroke.18. A method of stem cell treatment, comprising administering to asubject suffering from autoimmune diseases, cardiovascular diseases,and/or hematological diseases an effective amount of a stem cell or acombination of ligustilide and a stem cell, wherein the stem cell hasbeen treated with ligustilide.
 19. The method as claimed in claim 18,wherein the stem cell is at least one of an embryonic stem cell, anadult stem cell, and an induced pluripotent stem cell.
 20. The method asclaimed in claim 18, wherein the stem cell is an adipose-derived stemcell.
 21. The method as claimed in claim 18, which is for treatingcardiovascular diseases.
 22. The method as claimed in claim 21, which isfor treating stroke.